However, in head and neck squamous cell carcinoma (HNSCC), despite the high expression of epidermal growth factor receptor (EGFR), RTKI treatment often fails to show therapeutic efficacy in clinical trials, questioning their inclusion in standard therapy regimens. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.